• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oncotelic Therapeutcs Inc (OP:OTLC)

    0.0176 -0.0009 (-4.86%)
    Delayed Quote Updated: 3:55 PM EDT, Oct 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Oncotelic Therapeutcs Inc

    < Previous 1 2 3 4 5 6 7 Next >
    InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
    Via Investor Brand Network
    Topics Intellectual Property
    NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers
    Via Investor Brand Network
    Topics Death
    News headline image
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial Highlighting Innovative Therapeutics Pipeline
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Showcases Pipeline and CEO’s Intellectual Property Legacy
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
    Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets 
    Via News Direct
    News headline image
    With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial
    With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial 
    Via News Direct
    Topics Death
    News headline image
    OTCQB Venture Virtual Investor Conference Agenda Announced for August 7th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
    --News Direct-- 
    Via News Direct
    Oncotelic Therapeutics’ (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets
    --News Direct-- 
    Via News Direct
    News headline image
    Oncotelic Therapeutics' (OTCQB: OTLC) Lead Immunotherapy Candidate For Treating Deadly Cancers, OT-101, Could Hold Potential Applications In Multiple Multi-Billion Dollar Markets ↗
    Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. Its primary focus is on developing innovative drugs for oncology and infectious disease and aging. 
    Via Benzinga
    With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
    --News Direct-- 
    Via News Direct
    News headline image
    With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers ↗
    Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. 
    Via Benzinga
    The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge
    --News Direct-- 
    Via News Direct
    News headline image
    The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Charge ↗
    Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,... 
    Via Benzinga
    News headline image
    The Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Charge ↗
    Solid tumors are abnormal clumps of cells that form in various tissues or organs of the body. Unlike liquid or cystic tumors, solid tumors do not contain any liquid components. They can occur in bones,... 
    Via Benzinga
    News headline image
    Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.